154 related articles for article (PubMed ID: 36070368)
21. A molecular signature of well-differentiated oral squamous cell carcinoma reveals a resistance mechanism to metronomic chemotherapy and novel therapeutic candidates.
Kina S; Kawabata-Iwakawa R; Miyamoto S; Arasaki A; Sunakawa H; Kinjo T
J Drug Target; 2021 Dec; 29(10):1118-1127. PubMed ID: 33979258
[TBL] [Abstract][Full Text] [Related]
22. NOTCH1 Signaling in Head and Neck Squamous Cell Carcinoma.
Shah PA; Huang C; Li Q; Kazi SA; Byers LA; Wang J; Johnson FM; Frederick MJ
Cells; 2020 Dec; 9(12):. PubMed ID: 33322834
[TBL] [Abstract][Full Text] [Related]
23. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
[TBL] [Abstract][Full Text] [Related]
24. Oncogenic Role of ZFAS1 lncRNA in Head and Neck Squamous Cell Carcinomas.
Kolenda T; Guglas K; Kopczyńska M; Teresiak A; Bliźniak R; Mackiewicz A; Lamperska K; Mackiewicz J
Cells; 2019 Apr; 8(4):. PubMed ID: 31010087
[TBL] [Abstract][Full Text] [Related]
25. Elevated exosomal lysyl oxidase like 2 is a potential biomarker for head and neck squamous cell carcinoma.
Sanada T; Islam A; Kaminota T; Kirino Y; Tanimoto R; Yoshimitsu H; Yano H; Mizuno Y; Okada M; Mitani S; Ugumori T; Tanaka J; Hato N
Laryngoscope; 2020 May; 130(5):E327-E334. PubMed ID: 31219623
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of the long non-coding RNA CASC9 as a biomarker for squamous cell carcinoma.
Sassenberg M; Droop J; Schulz WA; Dietrich D; Loick SM; Wiek C; Scheckenbach K; Gaisa NT; Hoffmann MJ
BMC Cancer; 2019 Aug; 19(1):806. PubMed ID: 31412811
[TBL] [Abstract][Full Text] [Related]
27. Excavating novel diagnostic and prognostic long non-coding RNAs (lncRNAs) for head and neck squamous cell carcinoma: an integrated bioinformatics analysis of competing endogenous RNAs (ceRNAs) and gene co-expression networks.
Yang L; Lu P; Yang X; Li K; Chen X; Qu S
Bioengineered; 2021 Dec; 12(2):12821-12838. PubMed ID: 34898376
[TBL] [Abstract][Full Text] [Related]
28. Interferon-alpha enhances the antitumour activity of EGFR-targeted therapies by upregulating RIG-I in head and neck squamous cell carcinoma.
Ma H; Jin S; Yang W; Zhou G; Zhao M; Fang S; Zhang Z; Hu J
Br J Cancer; 2018 Feb; 118(4):509-521. PubMed ID: 29348488
[TBL] [Abstract][Full Text] [Related]
29. Genomics and precision surgery for head and neck squamous cell carcinoma.
Galmiche A; Saidak Z; Bouaoud J; Mirghani H; Page C; Dakpé S; Clatot F
Cancer Lett; 2020 Jul; 481():45-54. PubMed ID: 32272147
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
[TBL] [Abstract][Full Text] [Related]
31. A novel comprehensive immune-related gene signature as a promising survival predictor for the patients with head and neck squamous cell carcinoma.
Fang R; Iqbal M; Chen L; Liao J; Luo J; Wei F; Wen W; Sun W
Aging (Albany NY); 2021 Apr; 13(8):11507-11527. PubMed ID: 33867351
[TBL] [Abstract][Full Text] [Related]
32. Three distinct genomic subtypes of head and neck squamous cell carcinoma associated with clinical outcomes.
Lee DJ; Eun YG; Rho YS; Kim EH; Yim SY; Kang SH; Sohn BH; Kwon GH; Lee JS
Oral Oncol; 2018 Oct; 85():44-51. PubMed ID: 30220319
[TBL] [Abstract][Full Text] [Related]
33. Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia-Related Head and Neck Cancer.
Montanuy H; Martínez-Barriocanal Á; Antonio Casado J; Rovirosa L; Ramírez MJ; Nieto R; Carrascoso-Rubio C; Riera P; González A; Lerma E; Lasa A; Carreras-Puigvert J; Helleday T; Bueren JA; Arango D; Minguillón J; Surrallés J
Clin Cancer Res; 2020 Jun; 26(12):3044-3057. PubMed ID: 32005748
[TBL] [Abstract][Full Text] [Related]
34. Harnessing the role of epigenetic histone modification in targeting head and neck squamous cell carcinoma.
Suchanti S; Stephen BJ; Awasthi S; Awasthi SK; Singh G; Singh A; Mishra R
Epigenomics; 2022 Mar; 14(5):279-293. PubMed ID: 35184601
[TBL] [Abstract][Full Text] [Related]
35. Reduced proliferation and colony formation of head and neck squamous cell carcinoma (HNSCC) after dual targeting of EGFR and hedgehog pathways.
Liebig H; Günther G; Kolb M; Mozet C; Boehm A; Dietz A; Wichmann G
Cancer Chemother Pharmacol; 2017 Feb; 79(2):411-420. PubMed ID: 28110457
[TBL] [Abstract][Full Text] [Related]
36. The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.
Martin D; Abba MC; Molinolo AA; Vitale-Cross L; Wang Z; Zaida M; Delic NC; Samuels Y; Lyons JG; Gutkind JS
Oncotarget; 2014 Oct; 5(19):8906-23. PubMed ID: 25275298
[TBL] [Abstract][Full Text] [Related]
37. Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer.
Kang HN; Kim JH; Park AY; Choi JW; Lim SM; Kim J; Shin EJ; Hong MH; Pyo KH; Yun MR; Kim DH; Lee H; Yoon SO; Kim DH; Park YM; Byeon HK; Jung I; Paik S; Koh YW; Cho BC; Kim HR
BMC Cancer; 2020 Apr; 20(1):316. PubMed ID: 32293356
[TBL] [Abstract][Full Text] [Related]
38. MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
Arantes LM; Laus AC; Melendez ME; de Carvalho AC; Sorroche BP; De Marchi PR; Evangelista AF; Scapulatempo-Neto C; de Souza Viana L; Carvalho AL
Oncotarget; 2017 Feb; 8(6):9911-9921. PubMed ID: 28039483
[TBL] [Abstract][Full Text] [Related]
39. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
[No Abstract] [Full Text] [Related]
40. Tipifarnib in Head and Neck Squamous Cell Carcinoma With
Ho AL; Brana I; Haddad R; Bauman J; Bible K; Oosting S; Wong DJ; Ahn MJ; Boni V; Even C; Fayette J; Flor MJ; Harrington K; Kim SB; Licitra L; Nixon I; Saba NF; Hackenberg S; Specenier P; Worden F; Balsara B; Leoni M; Martell B; Scholz C; Gualberto A
J Clin Oncol; 2021 Jun; 39(17):1856-1864. PubMed ID: 33750196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
